Exporting Contract Pharmaceutical Manufacturing to the US — US Drug Companies

Contract pharmaceutical manufacturing is a critical backbone of the US drug supply chain, enabling drug companies to outsource production of active pharmaceutical ingredients (APIs), finished dosage forms, and biologics. The US market, the largest pharmaceutical market globally, relies heavily on imports for both raw materials and finished products, with over 80% of API manufacturing now located overseas. For US drug companies seeking reliable, cost-effective, and compliant manufacturing partners, Latin America and Africa present a strategic sourcing opportunity. This page provides a comprehensive overview of the product specifications, supplier landscape, buyer profiles, certifications, pricing context, and how Coppermont facilitates these high-stakes trade relationships.

The pharmaceutical industry is governed by stringent regulatory standards, and contract manufacturing organizations (CMOs) and contract development and manufacturing organizations (CDMOs) must adhere to Good Manufacturing Practices (GMP) enforced by the US Food and Drug Administration (FDA). The product scope includes not only the physical manufacturing of drugs but also development services, packaging, labeling, and quality assurance. US drug companies increasingly turn to contract manufacturing to reduce capital expenditure, access specialized technologies, and scale production flexibly. The global contract manufacturing market for pharmaceuticals was valued at approximately $90 billion in 2022 and is projected to grow at a compound annual growth rate (CAGR) of 7.5% through 2030, driven by demand for generics, biologics, and complex therapeutics [1].

Product Specifications and Grades Relevant to US Buyers

Contract pharmaceutical manufacturing encompasses a wide range of products and services, each with specific technical and regulatory requirements. The key categories include:

• Active Pharmaceutical Ingredients (APIs): These are the biologically active components of drugs. API manufacturing requires precise chemical synthesis or biological fermentation, with purity levels typically exceeding 99% for small molecules. US buyers demand APIs that meet United States Pharmacopeia (USP) or National Formulary (NF) standards, with full impurity profiles and stability data. For biologics, APIs are often proteins or peptides requiring cold-chain logistics and stringent biosafety levels.

• Finished Dosage Forms (FDFs): These include tablets, capsules, injectables, creams, and oral liquids. Specifications cover dissolution rates, uniformity of dosage, sterility (for parenterals), and stability under various storage conditions. US FDA requires that each batch meets the approved New Drug Application (NDA) or Abbreviated New Drug Application (ANDA) specifications. For generic drugs, bioequivalence to the reference listed drug is mandatory.

• Packaging and Labeling: Contract manufacturers often provide primary and secondary packaging services, including blister packs, bottles, vials, and syringes. US drug companies require compliance with the Drug Supply Chain Security Act (DSCSA), which mandates serialization and traceability at the package level. Packaging materials must be approved for drug contact and meet USP <661> or <671> standards for plastic and glass containers.

• Development Services: Many CMOs/CDMOs offer formulation development, analytical method validation, and scale-up from lab to commercial batches. These services are graded by the phase of clinical trials: Phase I (small-scale, flexible), Phase II (mid-scale, process optimization), and Phase III (large-scale, validation batches). US buyers often seek partners with experience in regulatory filings (IND, NDA, ANDA) and pre-approval inspections.

The grades and specifications required depend on the drug type: small molecules (typically synthetic, requiring chemical purity), large molecules (biologics, requiring cell line development and purification), and specialty drugs (e.g., oncology, hormones, controlled substances). For controlled substances, US Drug Enforcement Administration (DEA) registration is required, adding a layer of compliance.

LATAM and Africa Supplier Landscape

Latin America and Africa are emerging as significant hubs for contract pharmaceutical manufacturing, offering competitive advantages in cost, proximity to the US, and growing regulatory maturity.

Latin America: The region has a well-established pharmaceutical industry, with key players in Mexico, Brazil, Argentina, Colombia, and Chile. Mexico, in particular, benefits from the United States-Mexico-Canada Agreement (USMCA), which facilitates trade and regulatory alignment. Mexican CMOs often have FDA-inspected facilities and produce both APIs and FDFs for the US market. Brazil has a large domestic market and a robust regulatory agency (ANVISA) that aligns with international standards. However, Brazil’s complex tax and regulatory environment can be a barrier for export-focused suppliers. Argentina and Colombia have growing CDMO sectors, particularly for generics and injectables. According to a 2023 report by the International Trade Administration, US imports of pharmaceutical products from Mexico exceeded $5 billion annually, with a significant portion attributed to contract manufacturing [2].

Africa: The African pharmaceutical manufacturing sector is smaller but rapidly developing, driven by initiatives like the African Continental Free Trade Area (AfCFTA) and the African Medicines Agency (AMA). South Africa is the most advanced, with several FDA-approved facilities producing antiretrovirals, antibiotics, and oncology drugs. Egypt, Kenya, and Nigeria are also expanding their manufacturing capabilities, often supported by partnerships with global health organizations. African manufacturers offer cost advantages, particularly for generic drugs, and are increasingly investing in GMP compliance. However, infrastructure challenges and regulatory harmonization remain hurdles. The African Development Bank estimates that Africa imports over 70% of its pharmaceuticals, creating a strong domestic demand that also supports export capacity [3].

For US drug companies, sourcing from LATAM offers shorter lead times (2–4 weeks shipping vs. 6–8 weeks from Asia) and cultural/linguistic proximity. Africa offers a lower-cost alternative for high-volume generics, though supply chain reliability must be carefully vetted.

US Buyer Types: Who Buys This and How They Procure

US drug companies that engage contract pharmaceutical manufacturing range from large multinationals to small biotech startups. Each buyer type has distinct procurement behaviors and requirements.

• Large Pharmaceutical Companies (e.g., Pfizer, Johnson & Johnson, Merck): These companies typically source contract manufacturing for capacity overflow, specialized technologies (e.g., high-potency APIs, biologics), or cost optimization. Procurement is managed through formal RFPs (Requests for Proposals) and long-term supply agreements (3–5 years). They require suppliers with a proven track record of FDA compliance, multiple site inspections, and robust quality systems. Specifications are highly detailed, and audits are common. They often seek partners with experience in their therapeutic areas.

• Generic Drug Manufacturers (e.g., Teva, Sandoz, Mylan): These buyers focus on cost efficiency and speed to market. They source both APIs and FDFs for high-volume products. Procurement cycles are shorter, and they often work with multiple suppliers to ensure supply security. Specifications are driven by ANDA requirements, and bioequivalence studies are critical. They value suppliers with a broad portfolio of FDA-approved products and the ability to handle complex regulatory filings.

• Biotech and Specialty Pharma Companies (e.g., Amgen, Gilead, Moderna): These companies often outsource entire development and manufacturing programs, especially for biologics and cell/gene therapies. They require CDMOs with advanced capabilities in cell culture, purification, and aseptic filling. Procurement is relationship-driven, with a focus on technical expertise, scalability, and intellectual property protection. They often engage in early-stage partnerships that extend through commercialization.

• Small and Mid-Sized Enterprises (SMEs): These buyers may lack in-house manufacturing capabilities and rely entirely on CMOs for production. They value flexibility, transparency, and responsive communication. Procurement is often project-based, with milestones tied to clinical trial phases. They need suppliers who can handle small batch sizes and provide regulatory support for IND filings.

Procurement processes typically involve pre-qualification (submission of facility master files, quality certificates), a request for quotation (RFQ) with detailed technical specifications, a site audit (in-person or virtual), and a quality agreement. Payment terms often include milestones or progress payments, with letters of credit for international transactions.

Certifications and Import Requirements

Compliance with US regulations is non-negotiable for contract pharmaceutical manufacturing. The following certifications and requirements are essential:

• FDA Good Manufacturing Practices (GMP): All facilities must comply with 21 CFR Part 210 and 211 (for drugs) and 21 CFR Part 600 (for biologics). FDA conducts routine inspections and pre-approval inspections for new products. A warning letter or import alert can halt shipments. Suppliers must maintain a Drug Master File (DMF) with the FDA for each API or product.

• USP/NF Standards: APIs and excipients must meet USP or NF monographs, which specify purity, identity, and potency. For biologics, USP chapters on biologics (e.g., <1043>) apply.

• DEA Registration: For controlled substances (Schedule II–V), both the manufacturer and the US importer must be registered with the DEA. Quotas may apply for Schedule II drugs.

• Drug Supply Chain Security Act (DSCSA): This act requires product serialization at the package level, with transaction history and verification. Suppliers must implement systems for unique product identifiers (UPIs) and interoperable data exchange.

• ISO Certifications: While not mandatory, ISO 9001 (quality management) and ISO 14001 (environmental management) are often preferred. ISO 13485 (medical devices) may apply for combination products.

• Import Requirements: US Customs and Border Protection (CBP) requires a commercial invoice, packing list, and bill of lading. Pharmaceutical imports must be accompanied by an FDA Prior Notice (submitted electronically) and, for some products, an FDA entry review. Controlled substances require DEA Form 236 for import permits. Biologics require a Biologics License Application (BLA) approval.

• Country-Specific Regulations: For LATAM suppliers, compliance with local regulations (e.g., COFEPRIS in Mexico, ANVISA in Brazil) is a prerequisite for export. For Africa, the South African Health Products Regulatory Authority (SAHPRA) is a recognized authority.

Pricing and Lead Time Context

Pricing for contract pharmaceutical manufacturing varies widely based on product complexity, batch size, and regulatory burden. General ranges:

• API Manufacturing: $500–$5,000 per kilogram for simple small molecules; $5,000–$50,000+ per kilogram for complex or high-potency APIs. Biologic APIs can cost $100,000–$1 million per kilogram.
• Finished Dosage Forms: $0.01–$0.50 per tablet for high-volume generics; $1–$10 per unit for specialty injectables or transdermal patches.
• Development Services: $50,000–$500,000 for formulation development and scale-up; $1–$5 million for full CDMO services through Phase III.

Lead times depend on capacity and regulatory status. For established products with existing DMFs, lead times are 4–8 weeks for APIs and 8–12 weeks for FDFs. For new products requiring development and regulatory filings, lead times can be 12–24 months. Shipping from LATAM to the US takes 2–4 weeks by sea; from Africa, 4–6 weeks. Air freight is faster (3–7 days) but significantly more expensive.

Price competitiveness is a key driver for US buyers, with LATAM often offering 10–20% cost savings compared to US-based manufacturing, and Africa offering 20–40% savings for certain generics. However, total cost of ownership includes quality assurance, logistics, and regulatory compliance costs.

How Coppermont Connects Suppliers to Buyers

Coppermont specializes in facilitating high-value trade between Latin America and Africa and the US market, including the complex pharmaceutical sector. Our advisory services cover every step of the transaction:

• Supplier Vetting: We conduct due diligence on CMOs/CDMOs, including GMP compliance audits, DMF verification, and regulatory history checks. We maintain a curated database of vetted suppliers in Mexico, Brazil, South Africa, and other key markets.
• Buyer Matching: We work with US drug companies to understand their specific needs—API type, dosage form, volume, regulatory timeline—and match them with pre-qualified suppliers. Our network includes large pharma, generic manufacturers, and biotech firms.
• Regulatory Support: We help suppliers prepare for FDA inspections, compile DMFs, and navigate DEA registration. For buyers, we assist with supplier audits and quality agreement negotiations.
• Logistics and Finance: We coordinate cold-chain shipping, customs clearance, and compliance with DSCSA serialization. Our trade finance solutions include letters of credit, purchase order financing, and milestone-based payments.
• Ongoing Relationship Management: We monitor supply performance, regulatory changes, and market dynamics to ensure long-term success.

Whether you are a US drug company seeking a reliable manufacturing partner or a Latin American or African CMO looking to enter the US market, Coppermont provides the expertise and network to make it happen. Contact our team today to start a conversation about your pharmaceutical supply chain needs.

Ready to source or supply contract pharmaceutical manufacturing? Contact Coppermont for a consultation.